Efficacy and Safety of Serplulimab With Chemotherapy and Aspirin in Untreated Extensive-Stage Small Cell Lung Cancer

Clinical trial NCT06554535 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06554535
Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Extensive-Stage Small Cell Lung Cancer Treatment-naïve for Systemic Therapy Targeting Extensive-Stage Small Cell Lung Cancer ECOG Performance Status Score of 0 or 1 Expected Survival ≥3 Months

Start date: 2024-10-01
Primary completion: 2026-10-01
Enrollment: 43

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.